Business context and reporting period
This summary covers Ekso Bionics Holdings, Inc.’s unaudited Form 10-Q for the three months ended March 31, 2022. The company designs and sells medical and industrial exoskeleton products through its EksoHealth and EksoWorks segments. The request metadata names Chronoscale Holdings Corp., but the filing identifies Ekso Bionics Holdings, Inc. as the registrant (Nasdaq: EKSO).
Financial performance and position
Amounts below are in thousands of dollars, except per-share data and percentages.
| Metric | Q1 2022 | Q1 2021 / prior date |
|---|---|---|
| Revenue | $2,567 | $1,910 |
| Gross profit / margin | $1,209 / 47% | $1,235 / 65% |
| Operating expenses | $5,446 | $4,374 |
| Operating loss | $(4,237) | $(3,139) |
| Net loss | $(4,620) | $(3,670) |
| Net loss per share, basic and diluted | $(0.36) | $(0.34) |
| Cash from operating activities | $(4,206) | $(2,000) |
| Cash and working capital | $36,176 cash; $37,153 working capital | $40,406 cash at Dec. 31, 2021; working capital then $40.9 million |
| Total assets / liabilities | $44,242 / $10,756 | $49,166 / $11,947 at Dec. 31, 2021 |
The company reported $34.2 million of estimated unrestricted cash after accounting for $2.0 million required under its secured-loan liquidity covenant. Its $2.0 million Pacific Western Bank term loan matures in August 2023; the company reported covenant compliance. No financing cash inflow occurred in Q1 2022, compared with $38.7 million provided by financing in Q1 2021.
Material changes versus the prior comparable period
- Revenue rose 34%, primarily on higher EksoWorks EVO vest sales and recognition of $280,000 in previously deferred royalties under an expired license and distribution agreement. EksoWorks revenue increased to $686,000 from $183,000; EksoHealth revenue was $1.881 million, compared with $1.727 million.
- Gross profit declined 2% and gross margin fell 18 percentage points to 47%. Management cited higher EksoHealth service costs, product mix, and increased inventory costs amid supply shortages; the royalty recognition partly offset these pressures.
- Operating expenses grew 25%. Research and development increased 66% with product development activity and headcount; general and administrative costs rose 42%, including executive compensation, stock-based compensation and former CEO severance. Sales and marketing expense declined 9%.
- Operating cash use more than doubled, increasing by $2.2 million, which management attributed to business-development payments, higher compensation and inventory purchases. Cash declined by $4.23 million during the quarter.
Outlook, commentary, risks and unusual items
- No specific revenue, earnings or margin guidance was provided. Management stated it believed unrestricted cash was sufficient to fund operations beyond one year from issuance of the statements.
- Management reported booking 23 EksoNR units in Q1 and described some recovery in demand following pandemic-related disruptions, while noting continuing uncertainty over COVID-19 impacts and customer purchasing patterns.
- Supply constraints and longer lead times affecting electronic components, semiconductors, batteries, metals, plastics and manufacturing services may pressure costs and deliveries. Purchase obligations totaled $3.46 million as of March 31, 2022, primarily for inventory and manufacturing.
- Other risks include long and variable sales cycles, customer adoption and reimbursement, competition, medical-device regulation and clinical evidence, foreign-exchange exposure, and reliance on a limited number of customers. One customer represented 11% of Q1 revenue; one customer represented at least 10% of receivables at quarter-end.
- Leadership changed during the quarter: Steven Sherman became CEO and Scott Davis became President and COO in January; former CEO Jack Peurach departed, and Chief Commercial Officer William Shaw resigned effective March 11.
- Warrant liabilities were $1.65 million, measured using Level 3 valuation inputs; remeasurement produced a $100,000 loss. Management said pending or threatened legal matters were not expected to materially affect the financial statements. No material changes to previously disclosed risk factors were identified.
Important facts for investors to verify
- Confirm the registrant identity: the supplied filing is Ekso Bionics Holdings, Inc.’s 10-Q, not a filing identified as Chronoscale Holdings Corp.
- Track whether revenue growth translates into improved gross margin, particularly as supply costs and service activity evolve.
- Monitor operating cash use, unrestricted cash, and the company’s ability to maintain the loan’s liquidity covenant through the August 2023 maturity.
- Assess whether the Q1 royalty recognition was non-recurring and how recurring subscription, service and product revenues develop.
- Review supply-chain, customer concentration, foreign-exchange and demand risks, as well as potential dilution from outstanding warrants and equity awards.